Triple-Negative Breast Cancer | Topics

Axillary ultrasound and biopsy appear to be an effective strategy to identify nodal disease in patients with early-stage triple-negative breast cancer.

The study from Cancer Discovery examined a 3-case autopsy series, finding associations between TROP2 absence and limited clinical responses to sacituzumab govitecan for patients with metastatic triple-negative breast cancer.

Circulating tumor DNA should be utilized early to help detect relapse in patients with triple-negative breast cancer.

Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.

Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.

Atezolizumab will no longer be available for the treatment of patients with PD-L1–positive triple-negative breast cancer following withdrawal of the indication by the agent’s developer.

Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer.